CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next ...

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls.

While the fear of cancer looms large in the minds of many, the condition's vague indicators make it hard to know when genuine ...

A new mum put her symptoms of fatigue and breathlessness down to pregnancy. But tests finally revealed the devastating ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...